ArticleScientific reports2025
Synthesis, comprehensive in silico studies, and cytotoxicity evaluation of novel quinazolinone derivatives as potential anticancer agents.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Design, synthesis, and insecticidal potency of novel 3-methyl-pyrazole derivatives against Culex pipiens larvae.Scientific reports · 2026Article
- Integrated synthesis, antiproliferative potential, andRSC advances · 2026Article
- Transformation of 3-(4-methoxybenzylidine)-5-(RSC advances · 2026Article
- QM/MM hybrid simulation of enzyme-Mn synergistic catalysis for quinazolinones: computational determination of activation energy and transition state.Frontiers in chemistry · 2026Article
- New Quinazolin-4(3Molecules (Basel, Switzerland) · 2025Article
- Quinazolinone derivatives as potential anti‑tumor agents: Structural features and molecular mechanisms in inducing cell death (Review).International journal of molecular medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Quinazolinone derivatives exhibit significant synthetic and biological properties, making them valuable candidates for anticancer drug development. In this study, we synthesized novel quinazolinone derivatives via reactions of the previously unreported 4H-benzoxazin-4-one derivative (2) with various nitrogen nucleophiles, such as hydrazine hydrate and ammonium acetate, which yielded hydrazide and quinazolinone derivatives (3-6). Further modifications were achieved through reactions with carbon electrophiles and carbonyl compounds (e.g., phthalic anhydride, phenyl isothiocyanate, potassium cyanate, and pyrazole carbaldehyde), resulting in an expanded library of novel quinazolinone derivatives (7-15). The structures of all synthesized compounds were confirmed by spectroscopic and microanalytical techniques. In vitro cytotoxicity evaluations (mean IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.